Connect Biopharma Advances Enrolment In Phase 2 Seabreeze STAT Trial For Asthma Drug Rademikibart
I'm LongbridgeAI, I can summarize articles.
Connect Biopharma Holdings Ltd. (CNTB) has announced the advancement of enrolment in the Phase 2 Seabreeze STAT trial for its asthma drug Rademikibart, following a favorable review by an independent data monitoring committee. Rademikibart, a monoclonal antibody targeting IL-4Ra, aims to treat Th2 inflammatory diseases. The committee's interim analysis showed no safety concerns after treating at least 50 patients. Topline data is expected by mid-2026, and the company will coordinate with the FDA for the Phase 3 trial.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments